Welltower Valuation

Welltower Inc is a real estate investment trust that invests in healthcare infrastructure.

At 5.78 billion USD revenue, growing at 22.65 %, with 2.44 % net profit margin for 2022 Welltower is overvalued, according to Wolfteam Ltd.'s projections and estimates.

Welltower's intrinsic value is 27 billion USD compared to Welltower's current market capitalization of 49.73 billion USD.

This is excerpt from Welltower's third quarter, 2023 earnings report: 

FOR IMMEDIATE RELEASE
October 30, 2023
For more information contact:
Tim McHugh (419) 247-2800
Welltower Reports Third Quarter 2023 Results
Toledo, Ohio, October 30, 2023…..Welltower Inc. (NYSE:WELL) today announced results for the quarter ended September 30,
2023.
Recent Highlights
• Reported net income attributable to common stockholders of $0.24 per diluted share
• Reported normalized funds from operations ("FFO") attributable to common stockholders of $0.92 per diluted share
• Reported total portfolio year-over-year same store NOI ("SSNOI") growth of 14.1%, driven by SSNOI growth in our Seniors
Housing Operating ("SHO") portfolio of 26.1%
• SHO portfolio year-over-year same store ("SS") revenue increased 9.8% in the third quarter, driven by 220 basis points
("bps") of year-over-year average occupancy growth and Revenue Per Occupied Room ("RevPOR") growth of 6.9%
• SHO portfolio year-over-year SSNOI margin expanded by 330 bps driven primarily by strong RevPOR growth which
continued to meaningfully outpace Expense per Occupied Room ("ExpPOR") growth
• During the third quarter, we completed $1.4 billion of pro rata acquisitions and loan funding. Year to date as of October 30,
2023, we have completed $3.0 billion of pro rata gross investments exclusive of development funding
• As of September 30, 2023, we had approximately $6.7 billion of available liquidity inclusive of $2.7 billion of available cash
and restricted cash and full capacity under our $4.0 billion line of credit
• Improved net debt to Adjusted EBITDA to 5.14x at September 30, 2023 from 6.93x at September 30, 2022
• Revised full year 2023 net income attributable to common stockholders outlook to a range of $0.91 to $0.95 per diluted share
as compared to previous guidance of $0.75 to $0.84 per diluted share. Full year normalized FFO attributable to common
stockholders guidance has been revised to a range of $3.59 to $3.63 per diluted share as compared to previous guidance of
$3.51 to $3.60 per diluted share